Patent 9549918
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Active provider: Google · gemini-2.5-pro
No PTAB proceedings on file. This patent has not been challenged through Inter Partes Review, Post-Grant Review, or Covered Business Method review at the USPTO. The absence is itself a signal — well-asserted patents eventually attract IPRs.
Cases on file (4)
Group view →Specific litigation cases in our database that name US patent 9549918. The free-form analysis below may also discuss cases beyond this list.
- Veloxis Pharmaceuticals AS v. Zydus Cadila et al.filed Apr 23, 20261:26-cv-00467Delaware District CourtOpen
Defendants: Zydus Cadila and Zydus Lifesciences Ltd
Other patents asserted: 11419823, 10864199, 8685998, 8664239, 11123331, 12403095, 10166190, 11110081, 12083103
The accused products are the 0.75 mg, 1 mg, and 4 mg extended-release tacrolimus tablets sold under the brand name ENVARSUS XR.
- Veloxis Pharmaceuticals, Inc. v. Glenmark Pharmaceuticals Inc.filed Apr 14, 20251:25-cv-00458U.S. District Court for the District of Delawareongoing
Defendants: Glenmark Pharmaceuticals Inc.
- Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc. et al.filed Jul 7, 20221:22-cv-00909U.S. District Court for the District of Delawareoutcome not detailed
Defendants: Accord Healthcare, Inc. and Intas Pharmaceuticals LTD
- U.S. District Court for the District of Delawaresettled
Defendants: Sun Pharmaceutical Industries Ltd.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Known Litigation Involving US Patent 9,549,918
As of April 26, 2026, US patent 9,549,918, assigned to Veloxis Pharmaceuticals Inc., is involved in ongoing and past litigation, primarily related to generic drug applications. These cases fall under the Hatch-Waxman Act, where a generic drug manufacturer challenges the patents of a branded drug, in this case, Envarsus XR® (tacrolimus extended-release tablets).
Here is a list of known litigation involving this patent:
Recently Filed Litigation (2026):
- Plaintiff: Veloxis Pharmaceuticals, Inc.
- Defendants: Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Ltd.
- Jurisdiction: U.S. District Court for the District of Delaware
- Case Number: 1:26-cv-00467
- Filing Date: April 23, 2026
- Status: This case was recently filed and is in its early stages. The complaint alleges patent infringement based on the defendants' Abbreviated New Drug Application (ANDA) to market a generic version of Envarsus XR®.
Ongoing and Recently Settled Litigation (2025):
Plaintiff: Veloxis Pharmaceuticals, Inc.
Defendant: Glenmark Pharmaceuticals Inc.
Jurisdiction: U.S. District Court for the District of Delaware
Case Number: 1:25-cv-00458
Filing Date: April 14, 2025
Status: This case is listed as ongoing.
Plaintiff: Veloxis Pharmaceuticals Inc.
Defendant: Sun Pharmaceutical Industries Ltd.
Jurisdiction: U.S. District Court for the District of Delaware
Filing Date: Not specified, but active in 2026.
Status: Settled. Veloxis and Sun reached an agreement in April 2026, preventing a generic version of Envarsus XR from Sun until May 2028. A bench trial that was scheduled for the week of the settlement was averted.
Past Litigation (2022):
- Plaintiff: Veloxis Pharmaceuticals, Inc.
- Defendants: Accord Healthcare, Inc. and Intas Pharmaceuticals LTD
- Jurisdiction: U.S. District Court for the District of Delaware
- Case Number: 1:22-cv-00909
- Filing Date: July 7, 2022
- Status: The complaint alleged that the defendants' ANDA for generic tacrolimus extended-release tablets infringed on six Veloxis patents, including the '918 patent. Veloxis sought to prevent the manufacturing and marketing of the generic product before the patents expired. The specific outcome of this case is not detailed in the provided search results, but it is part of the broader enforcement strategy for the Envarsus XR® patent portfolio.
Generated 5/1/2026, 5:59:05 PM